Sanofi Reports Phase 3 extension Data for Iptacopan in Urothelial carcinoma

Sanofi today announced Phase 3 extension results for Iptacopan in patients with Urothelial carcinoma. The study demonstrated that Iptacopan demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Urothelial carcinoma and support the continued development of Iptacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Iptacopan was consistent with previous observations, with no new safety signals identified.